Clinical observation on treatment of primary hepatocarcinoma patients with continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE
10.3969/j.issn.1671-8348.2015.24.020
- VernacularTitle:替吉奥持续低剂量口服联合小剂量 TACE 治疗原发性肝癌疗效观察
- Author:
Xiaohong YU
;
Jibin LOU
;
Jixi YAN
;
Aixia DING
- Publication Type:Journal Article
- Keywords:
liver cancer;
chemoembolization,therapeutic;
brachytherapy;
Tegafur,Gimeracil and Oteracil Potassium Capsules
- From:
Chongqing Medicine
2015;(24):3367-3369
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse reaction of continuous low-dose oral Tegafur,Gimeracil and Oter-acil Potassium Capsules in combination with small dose of transcatheter arterial chemoembolization(TACE)in the treatment of pri-mary hepatocarcinoma patients.Methods A total of 92 primary hepatocarcinoma patients who were unable or unwilling to surgery. Patients were divided into treatment group and control group,with each consisted of 46 cases.The treatment group was given con-tinuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules in combination with small dose of TACE,and the control group was given small dose TACE.All study subjects were reviewed DSA and CT.tumor angiogenesis and tumor staining,Karnof-sky Performance Scores(KPS),postoperative adverse events and complications was evaluated.PFS and the survival rate of three months,six months,one year and two years was estimated.Results Tumor angiogenesis and staining were significantly lower in treatment group than those of the control group(P <0.05).Patients in the two groups had the same rates of side effects and com-plications(P >0.05).KPS scores in the two groups had no significant difference before and after treatment(P >0.05 ).PFS,one year and two years survival rate were better in treatment group than in the control group(P <0.05).Conclusion Combined appli-cation of continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE was significantly su-perior to TACE alone in the treatment of primary hepatocarcinoma patients.
